A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS
Completed
Hoffmann-La Roche
N/A
1969-12-31
To evaluate the safety and tolerance of long-term ganciclovir (DHPG) therapy for newly
diagnosed macular threatening Cytomegalovirus (CMV) retinitis in AIDS patients. To evaluate
the clinical response to a 52 week course of intravenous DHPG therapy. To evaluate the safety
and tolerance of long-term DHPG with concurrent treatment with zidovudine (AZT). (Patients
utilizing treatment with other anti-retroviral drugs will be considered for study entry on a
case by case basis.) To determine survival in this group of patients with AIDS and CMV
retinitis.
T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
Unknown status
University Hospital Birmingham
Phase 2
2009-09-01
RATIONALE: An infusion of cytomegalovirus-specific T lymphocytes may prevent or reduce
cytomegalovirus infection during the first year after a donor stem cell transplant.
PURPOSE: This randomized phase II trial is studying T-lymphocyte infusion to see how well it
works compared with standard therapy in treating patients at risk of cytomegalovirus
infection after a donor stem cell transplant.
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Completed
National Cancer Institute (NCI)
2010-12-01
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV)
infection caused by a stem cell transplant.
PURPOSE:This clinical trial studies infection prophylaxis and management in treating
cytomegalovirus infection in patients with hematologic malignancies previously treated with
donor stem cell transplant.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
